Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

INTRODUCTION: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score. METHODS: Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Masatoshi, Finn, Richard S., Cheng, Ann-Lii, Zhu, Andrew X., Ducreux, Michel, Galle, Peter R., Sakamoto, Naoya, Kato, Naoya, Nakano, Michitaka, Jia, Jing, Vogel, Arndt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601852/
https://www.ncbi.nlm.nih.gov/pubmed/37901766
http://dx.doi.org/10.1159/000529996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601852/
https://www.ncbi.nlm.nih.gov/pubmed/37901766
http://dx.doi.org/10.1159/000529996

Ejemplares similares